Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients

Neil L BerinsteinSunnybrook Health Sciences Centre; Toronto, Ontario, Canada

Mohan KarkadaImmunovaccine, Inc.; Halifax, Nova Scotia, Canada

Amit M OzaPrincess Margaret Cancer Center; University Health Network; Toronto, Ontario, Canada

Kunle OdunsiRoswell Park Cancer Institute; Buffalo, NYUSA

Jeannine A VillellaWinthrop-University Hospital; Mineola, NYUSA

John J NemunaitisMary Crowley Cancer Research Center; Dallas, TXUSA

Michael A MorseDuke University Medical Center; Durham, NCUSA

Tanja PejovicOregon Health & Science University; Portland, ORUSA

James BentleyQEII Health Sciences Center; Halifax, Nova Scotia, Canada

Marc BuyseInternational Drug Development Institute (IDDI); Louvain la Neuve, Belgium

Rita NigamImmunovaccine, Inc.; Halifax, Nova Scotia, Canada

Genevieve M WeirImmunovaccine, Inc.; Halifax, Nova Scotia, Canada

Lisa D MacDonaldImmunovaccine, Inc.; Halifax, Nova Scotia, Canada

Tara QuintonImmunovaccine, Inc.; Halifax, Nova Scotia, Canada

Rajkannan RajagopalanImmunovaccine, Inc.; Halifax, Nova Scotia, Canada

Kendall SharpImmunovaccine, Inc.; Halifax, Nova Scotia, Canada

Andrea PenwellImmunovaccine, Inc.; Halifax, Nova Scotia, Canada

Leeladhar SammaturImmunovaccine, Inc.; Halifax, Nova Scotia, Canada

Tomasz BurzykowskiInternational Drug Development Institute (IDDI); Louvain la Neuve, Belgium

Marianne M StanfordImmunovaccine, Inc.; Halifax, Nova Scotia, Canada

Marc MansourImmunovaccine, Inc.; Halifax, Nova Scotia, CanadaCorrespondence[email protected]

Your download is now in progress and you may close this window